Potential investors with long-term visions have been long waiting for ENZC stock to shoot up drastically on its HIV treatment programs while the covid-19 race is over. In November 2020 the stock started soaring and could blast off to $0.60. When the hype was over ENZC kept being one of the popular penny stocks that one day could rocket to over $10. Right now it is “half-dead” by trading at a microscopically low $0.0735.
When will ENZC die?
Recently, CytoDyn announced a full clinical hold of the covid-19 program and a partial hold of the HIV program its CYDY stock went down from trending ranks. Soon it will surely become uninteresting biotech stock. The same fate is most likely waiting for ENZC as it is fading due to a lack of clinical updates. If IPF immune sales rocket ENZC will surely survive and reach record high prices.